Literature DB >> 26656708

Scanning Mutagenesis of Human Cytomegalovirus Glycoprotein gH/gL.

Eric P Schultz1, Jean-Marc Lanchy1, Erin E Ellerbeck1, Brent J Ryckman2.   

Abstract

UNLABELLED: The core, conserved function of the herpesvirus gH/gL is to promote gB-mediated membrane fusion during entry, although the mechanism is poorly understood. The human cytomegalovirus (HCMV) gH/gL can exist as either the gH/gL/gO trimer or the gH/gL/UL128/UL130/UL131 (gH/gL/UL128-131) pentamer. One model suggests that gH/gL/gO provides the core fusion role during entry into all cells within the broad tropism of HCMV, whereas gH/gL/UL128-131 acts at an earlier stage, by a distinct receptor-binding mechanism to enhance infection of select cell types, such as epithelial cells, endothelial cells, and monocytes/macrophages. To further study the distinct functions of these complexes, mutants with individual charged cluster-to-alanine (CCTA) mutations of gH and gL were combined to generate a library of 80 mutant gH/gL heterodimers. The majority of the mutant gH/gL complexes were unable to facilitate gB-mediated membrane fusion in transient-expression cell-cell fusion experiments. In contrast, these mutants supported the formation of gH/gL/UL128-131 complexes that could block HCMV infection in receptor interference experiments. These results suggest that receptor interactions with gH/gL/UL128-131 involve surfaces contained on the UL128-131 proteins but not on gH/gL. gH/gL/UL128-131 receptor interference could be blocked with anti-gH antibodies, suggesting that interference is a cell surface phenomenon and that anti-gH antibodies can block gH/gL/UL128-131 in a manner that is distinct from that for gH/gL/gO. IMPORTANCE: Interest in the gH/gL complexes of HCMV (especially gH/gL/UL128-131) as vaccine targets has far outpaced our understanding of the mechanism by which they facilitate entry and contribute to broad cellular tropism. For Epstein-Barr virus (EBV), gH/gL and gH/gL/gp42 are both capable of promoting gB fusion for entry into epithelial cells and B cells, respectively. In contrast, HCMV gH/gL/gO appears to be the sole fusion cofactor that promotes gB fusion activity, whereas gH/gL/UL128-131 expands cell tropism through a distinct yet unknown mechanism. This study suggests that the surfaces of HCMV gH/gL are critical for promoting gB fusion but are dispensable for gH/gL/UL128-131 receptor interaction. This underscores the importance of gH/gL/gO in HCMV entry into all cell types and reaffirms the complex as a candidate target for vaccine development. The two functionally distinct forms of gH/gL present in HCMV make for a useful model with which to study the fundamental mechanisms by which herpesvirus gH/gL regulates gB fusion.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26656708      PMCID: PMC4810707          DOI: 10.1128/JVI.01875-15

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  58 in total

1.  A viral regulator of glycoprotein complexes contributes to human cytomegalovirus cell tropism.

Authors:  Gang Li; Christopher C Nguyen; Brent J Ryckman; William J Britt; Jeremy P Kamil
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-23       Impact factor: 11.205

2.  Mutations in the amino terminus of herpes simplex virus type 1 gL can reduce cell-cell fusion without affecting gH/gL trafficking.

Authors:  Wenbo Zhou; Feng Chen; Yuri Klyachkin; Yuk Y Sham; Robert J Geraghty
Journal:  J Virol       Date:  2013-10-23       Impact factor: 5.103

3.  Mechanism for neutralizing activity by the anti-CMV gH/gL monoclonal antibody MSL-109.

Authors:  Ashley E Fouts; Laëtitia Comps-Agrar; Katharina F Stengel; Diego Ellerman; Allyn J Schoeffler; Søren Warming; Dan L Eaton; Becket Feierbach
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-19       Impact factor: 11.205

4.  Structural and biochemical studies of HCMV gH/gL/gO and Pentamer reveal mutually exclusive cell entry complexes.

Authors:  Claudio Ciferri; Sumana Chandramouli; Danilo Donnarumma; Pavel A Nikitin; Michael A Cianfrocco; Rachel Gerrein; Adam L Feire; Susan W Barnett; Anders E Lilja; Rino Rappuoli; Nathalie Norais; Ethan C Settembre; Andrea Carfi
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-26       Impact factor: 11.205

5.  Soluble Human Cytomegalovirus gH/gL/pUL128-131 Pentameric Complex, but Not gH/gL, Inhibits Viral Entry to Epithelial Cells and Presents Dominant Native Neutralizing Epitopes.

Authors:  John W Loughney; Richard R Rustandi; Dai Wang; Matthew C Troutman; Lawrence W Dick; Guanghua Li; Zhong Liu; Fengsheng Li; Daniel C Freed; Colleen E Price; Van M Hoang; Timothy D Culp; Pete A DePhillips; Tong-Ming Fu; Sha Ha
Journal:  J Biol Chem       Date:  2015-05-06       Impact factor: 5.157

6.  Human Cytomegalovirus gH/gL/gO Promotes the Fusion Step of Entry into All Cell Types, whereas gH/gL/UL128-131 Broadens Virus Tropism through a Distinct Mechanism.

Authors:  Momei Zhou; Jean-Marc Lanchy; Brent J Ryckman
Journal:  J Virol       Date:  2015-06-17       Impact factor: 5.103

7.  HCMV gH/gL/UL128-131 interferes with virus entry into epithelial cells: evidence for cell type-specific receptors.

Authors:  Brent J Ryckman; Marie C Chase; David C Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-03       Impact factor: 11.205

8.  Assembly and architecture of the EBV B cell entry triggering complex.

Authors:  Karthik Sathiyamoorthy; Jiansen Jiang; Yao Xiong Hu; Cynthia L Rowe; Britta S Möhl; Jia Chen; Wei Jiang; Elizabeth D Mellins; Richard Longnecker; Z Hong Zhou; Theodore S Jardetzky
Journal:  PLoS Pathog       Date:  2014-08-21       Impact factor: 6.823

9.  Antigenic Characterization of the HCMV gH/gL/gO and Pentamer Cell Entry Complexes Reveals Binding Sites for Potently Neutralizing Human Antibodies.

Authors:  Claudio Ciferri; Sumana Chandramouli; Alexander Leitner; Danilo Donnarumma; Michael A Cianfrocco; Rachel Gerrein; Kristian Friedrich; Yukti Aggarwal; Giuseppe Palladino; Ruedi Aebersold; Nathalie Norais; Ethan C Settembre; Andrea Carfi
Journal:  PLoS Pathog       Date:  2015-10-20       Impact factor: 6.823

10.  A site of varicella-zoster virus vulnerability identified by structural studies of neutralizing antibodies bound to the glycoprotein complex gHgL.

Authors:  Yi Xing; Stefan L Oliver; TuongVi Nguyen; Claudio Ciferri; Avishek Nandi; Julie Hickman; Cinzia Giovani; Edward Yang; Giuseppe Palladino; Charles Grose; Yasushi Uematsu; Anders E Lilja; Ann M Arvin; Andrea Carfí
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-27       Impact factor: 11.205

View more
  12 in total

1.  Specialization for Cell-Free or Cell-to-Cell Spread of BAC-Cloned Human Cytomegalovirus Strains Is Determined by Factors beyond the UL128-131 and RL13 Loci.

Authors:  Eric P Schultz; Jean-Marc Lanchy; Le Zhang Day; Qin Yu; Christopher Peterson; Jessica Preece; Brent J Ryckman
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

2.  Impact of Antibodies and Strain Polymorphisms on Cytomegalovirus Entry and Spread in Fibroblasts and Epithelial Cells.

Authors:  Xiaohong Cui; Daniel C Freed; Dai Wang; Ping Qiu; Fengsheng Li; Tong-Ming Fu; Lawrence M Kauvar; Michael A McVoy
Journal:  J Virol       Date:  2017-06-09       Impact factor: 5.103

3.  Polymorphisms in Human Cytomegalovirus Glycoprotein O (gO) Exert Epistatic Influences on Cell-Free and Cell-to-Cell Spread and Antibody Neutralization on gH Epitopes.

Authors:  Le Zhang Day; Cora Stegmann; Eric P Schultz; Jean-Marc Lanchy; Qin Yu; Brent J Ryckman
Journal:  J Virol       Date:  2020-03-31       Impact factor: 5.103

4.  Cytomegalovirus UL128 homolog mutants that form a pentameric complex produce virus with impaired epithelial and trophoblast cell tropism and altered pathogenicity in the guinea pig.

Authors:  Stewart Coleman; K Yeon Choi; Alistair McGregor
Journal:  Virology       Date:  2017-06-23       Impact factor: 3.616

5.  Platelet-derived growth factor-α receptor is the cellular receptor for human cytomegalovirus gHgLgO trimer.

Authors:  Anna Kabanova; Jessica Marcandalli; Tongqing Zhou; Siro Bianchi; Ulrich Baxa; Yaroslav Tsybovsky; Daniele Lilleri; Chiara Silacci-Fregni; Mathilde Foglierini; Blanca Maria Fernandez-Rodriguez; Aliaksandr Druz; Baoshan Zhang; Roger Geiger; Massimiliano Pagani; Federica Sallusto; Peter D Kwong; Davide Corti; Antonio Lanzavecchia; Laurent Perez
Journal:  Nat Microbiol       Date:  2016-06-06       Impact factor: 17.745

6.  A Homolog Pentameric Complex Dictates Viral Epithelial Tropism, Pathogenicity and Congenital Infection Rate in Guinea Pig Cytomegalovirus.

Authors:  Stewart Coleman; K Yeon Choi; Matthew Root; Alistair McGregor
Journal:  PLoS Pathog       Date:  2016-07-07       Impact factor: 6.823

7.  Differences in Growth Properties among Two Human Cytomegalovirus Glycoprotein O Genotypes.

Authors:  Julia Kalser; Barbara Adler; Michael Mach; Barbara Kropff; Elisabeth Puchhammer-Stöckl; Irene Görzer
Journal:  Front Microbiol       Date:  2017-08-22       Impact factor: 5.640

8.  Mutagenesis of Human Cytomegalovirus Glycoprotein L Disproportionately Disrupts gH/gL/gO over gH/gL/pUL128-131.

Authors:  Eric P Schultz; Qin Yu; Cora Stegmann; Le Zhang Day; Jean-Marc Lanchy; Brent J Ryckman
Journal:  J Virol       Date:  2021-08-10       Impact factor: 5.103

9.  Functional screening for anti-CMV biologics identifies a broadly neutralizing epitope of an essential envelope protein.

Authors:  Thomas J Gardner; Kathryn R Stein; J Andrew Duty; Toni M Schwarz; Vanessa M Noriega; Thomas Kraus; Thomas M Moran; Domenico Tortorella
Journal:  Nat Commun       Date:  2016-12-14       Impact factor: 14.919

10.  Fine Mapping the Interaction Between Dendritic Cell-Specific Intercellular Adhesion Molecule (ICAM)-3-Grabbing Nonintegrin and the Cytomegalovirus Envelope Glycoprotein B.

Authors:  Coraline Chéneau; Flora Coulon; Vanessa Porkolab; Franck Fieschi; Stéphanie Laurant; Diane Razanajaona-Doll; Jean-Jacques Pin; Eva Maria Borst; Martin Messerle; Céline Bressollette-Bodin; Franck Halary
Journal:  J Infect Dis       Date:  2018-07-02       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.